Mirabegron: pharmacoeconomic aspects of the use of the drug for the treatment of overactive bladder syndrome
According to the International Continence Society (ICS), symptoms of overactive bladder (OAB) are present in 17 % of the adult population of Europe. The prevalence of overactive bladder in Russia is unknown but is considered comparable to that in European countries. According to Russian guidelines,...
Saved in:
Main Authors: | O. I. Ivakhnenko (Author), E. V. Derkach (Author), V. S. Krysanova (Author), A. D. Ermolaeva (Author), K. A. Kokushkin (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic feasibility of using Mirabegron in patients with overactive bladder
by: I. N. Dyakov, et al.
Published: (2021) -
Mirabegron in the Management of Overactive Bladder Syndrome
by: O'Kane M, et al.
Published: (2022) -
Profile of mirabegron in the treatment of overactive bladder: place in therapy
by: Sharaf A, et al.
Published: (2017) -
Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
by: Luisa Gracio Ferreira Sartori, et al.
Published: (2023) -
Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
by: Shaw C, et al.
Published: (2023)